文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

基于疾病严重程度与死亡率的COVID-19插管决策:一项国际研究

Intubation Decision Based on Illness Severity and Mortality in COVID-19: An International Study.
PubMed 文献 · Crit Care Med · 2024-02-23
一句话结论重症COVID-19患者按SOFA<7或PaO2/FiO2>250的严重度标准早期插管,与30天死亡风险降低32%相关(校正HR 0.68)。

该前瞻性、多中心、观察性研究于2020年2月1日至2022年11月1日在美国和欧洲10家学术机构开展,纳入因COVID-19住院且入院后需插管的成人患者,排除因非COVID-19原因住院而SARS-CoV-2检测阳性者。早期有创机械通气(EIMV)定义为器官功能障碍较轻(SOFA<7或PaO2/FiO2>250)时插管,晚期有创机械通气(LIMV)定义为SOFA≥7且PaO2/FiO2≤250时插管。4464例患者中854例(19.1%)需要机械通气,其中EIMV组621例(72.7%)、LIMV组233例(27.3%);30天死亡EIMV组278例(42.2%)vs LIMV组88例(46.6%),p=0.28。逆概率治疗加权分析显示EIMV组30天死亡风险降低32%(校正HR 0.68;95%CI 0.52-0.90;p=0.008),插管后30天内死亡校正HR 0.70(95%CI 0.51-0.90;p=0.006)。作者认为,以客观严重度评估为指导的早期插管策略与死亡风险降低相关。

要点

  • 重症COVID-19患者按SOFA<7或PaO2/FiO2>250标准早期插管,校正后30天死亡风险降低32%(校正HR 0.68;95%CI 0.52-0.90;p=0.008)。
  • 以插管为起点计算30天内死亡,EIMV组风险同样较低(校正HR 0.70;95%CI 0.51-0.90;p=0.006)。
  • 未校正的30天死亡EIMV组42.2%(278例)vs LIMV组46.6%(88例),差异未达统计学显著(p=0.28)。
  • 854例需机械通气患者中72.7%被归入EIMV组、27.3%归入LIMV组,提示按严重度标准多数插管发生在器官功能障碍较轻时。
  • 作者认为,依据客观严重度评估及时插管很重要。

适用人群与场景

  • 成人(≥18岁)确诊SARS-CoV-2感染、因COVID-19住院且入院后需要插管的患者。
  • 排除因非COVID-19原因住院而SARS-CoV-2检测阳性的患者。
  • 研究场景为美国和欧洲10家学术机构住院期间。

诊断标准与关键阈值

  • 早期有创机械通气(EIMV):器官功能障碍较轻时插管,即SOFA<7或PaO2/FiO2>250。
  • 晚期有创机械通气(LIMV):SOFA≥7且PaO2/FiO2≤250时插管。

研究设计与关键结果

  • 研究设计:前瞻性、多中心、观察性研究,2020年2月1日至2022年11月1日在美国和欧洲10家学术机构开展。
  • 研究人群:4464例患者中854例(19.1%)需要机械通气;平均年龄60岁,男性61.7%,黑人19.3%。
  • 分组:EIMV组621例(72.7%),LIMV组233例(27.3%)。
  • 主要终点(入院30天内死亡):EIMV组278例(42.2%)vs LIMV组88例(46.6%),p=0.28。
  • 逆概率治疗加权分析:EIMV组30天死亡风险降低32%(校正HR 0.68;95%CI 0.52-0.90;p=0.008)。
  • 次要终点(插管后30天内死亡,不论插管距入院时间):校正HR 0.70(95%CI 0.51-0.90;p=0.006)。

证据类型、等级与局限

  • 证据类型:前瞻性、多中心、观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在重症COVID-19病例中,以特定严重度标准(SOFA<7或PaO2/FiO2>250)为指导的早期插管策略与死亡风险降低相关。
  • 作者认为,这些发现强调基于客观严重度评估及时干预的重要性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the impact of intubation timing, guided by severity criteria, on mortality in critically ill COVID-19 patients, amidst existing uncertainties regarding optimal intubation practices.

DESIGN: Prospective, multicenter, observational study conducted from February 1, 2020, to November 1, 2022.

SETTING: Ten academic institutions in the United States and Europe.

PATIENTS: Adults (≥ 18 yr old) confirmed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and hospitalized specifically for COVID-19, requiring intubation postadmission. Exclusion criteria included patients hospitalized for non-COVID-19 reasons despite a positive SARS-CoV-2 test.

INTERVENTIONS: Early invasive mechanical ventilation (EIMV) was defined as intubation in patients with less severe organ dysfunction (Sequential Organ Failure Assessment [SOFA] < 7 or Pa o2 /F io2 ratio > 250), whereas late invasive mechanical ventilation (LIMV) was defined as intubation in patients with SOFA greater than or equal to 7 and Pa o2 /F io2 ratio less than or equal to 250.

MEASUREMENTS AND MAIN RESULTS: The primary outcome was mortality within 30 days of hospital admission. Among 4464 patients, 854 (19.1%) required mechanical ventilation (mean age 60 yr, 61.7% male, 19.3% Black). Of those, 621 (72.7%) were categorized in the EIMV group and 233 (27.3%) in the LIMV group. Death within 30 days after admission occurred in 278 patients (42.2%) in the EIMV and 88 patients (46.6%) in the LIMV group ( p = 0.28). An inverse probability-of-treatment weighting analysis revealed a statistically significant association with mortality, with patients in the EIMV group being 32% less likely to die either within 30 days of admission (adjusted hazard ratio [HR] 0.68; 95% CI, 0.52-0.90; p = 0.008) or within 30 days after intubation irrespective of its timing from admission (adjusted HR 0.70; 95% CI, 0.51-0.90; p = 0.006).

CONCLUSIONS: In severe COVID-19 cases, an early intubation strategy, guided by specific severity criteria, is associated with a reduced risk of death. These findings underscore the importance of timely intervention based on objective severity assessments.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Chalkias A, Huang Y, Ismail A, et al. Intubation Decision Based on Illness Severity and Mortality in COVID-19: An International Study. Crit Care Med. 2024. PMID: 38391282. doi:10.1097/CCM.0000000000006229

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。